alterations (CNA) and tumor ploidy were estimated by the tool Battenberg (v1.5.0) 6 . Our scripts calculated the mutational burden (i.e. total number of mutations), flagged mutated and/or genes with CNA associated with cancer (according to multiple sources listed below) and then used the database CIViC to identify mutations and CNA that were predictive of sensitivity to specific drugs (i.e. actionable) 7 . The sources of cancer---associated genes were:
allOnco from the Bushman Lab, Database of Curated Mutations (doCM), Network of Cancer Genes (NCG), TAG and Genetic Association Database (GAD) [8] [9] [10] . All the scripts were developed using the R language and software environment (v3.3.3).
RNA Workflow: RNAseq data processing
Raw RNAseq data from tumor samples (CD138+ cells), in fastq format, was mapped to the reference genome (GRCh37) using the tool STAR (v2.5) 11 . Gene---level features were quantified by featureCounts from the Subread package (v1.5.1) 12 . We filtered expression data to include genes with cpm (counts per million) > 1 in at least 10% of the samples. Filtered data was then normalized by TMM from the package edgeR and voom from the package Limma 13, 14 . The R package VariancePartition was used to determine the contribution of batch effect, which was then removed by applying linear regression and keeping the residuals for downstream analysis 15 .
RNA Workflow: RNAseq Data Analysis
One of the challenges in the analysis of gene expression in MM is the lack of normal control samples to use for differential expression. For this reason, we defined outliers in each sample as genes that are over---or under---expressed compared to the other samples in the cohort. Outliers were then determined by z---scores. Genes with a z---score > 1.5 were considered over---expressed, while genes with a z---score < ---1.5 were considered under---expressed.
Zscore for each gene was calculated as = ( % − )/ , where Xi is the expression of gene i, μ is the average expression of gene i in the sample space, and σ is its standard deviation. Pathway activation was calculated by the tool GSVA (Gene---set Variation Analysis), using pathway definitions from different sources (see below) 16 . GSVA calculates relative enrichment of a gene set in each sample across the sample space, allowing for sample---wise comparison of gene set enrichment across a dataset. A positive enrichment value for a sample indicates overall higher expression of the genes in the pathway in the sample, compared to the other samples analyzed. This may suggest increased activity of the pathway. We used the following pathways from various sources, such as Reactome and Biocarta: XBP1s_activates_chaperone_genes, mTOR_signalling, DNA_repair, Interleukin6_signaling, PI3K_AKT_activation, Signaling_by_Hedgehog, MAPK 17, 18 . The FGFR3 gene set was based on a signature that we previously determined through network analysis of MM patients 19 .
The tool L1000CDS2 was used to reverse---match patient samples with gene expression profiles induced by drugs on different cell lines retrieved from the LINCS project 20 . Outlier genes, both UP and DOWN regulated, were provided to the tool, which identified small molecule signatures that reversed the input signature.
All the scripts were developed using the R language and software environment (v3.3.3).
Prioritization of Drug Recommendations
Recommended drugs were prioritized based on their specific association with MM according to the available evidence in the CIViC database and organized in three tiers: (I) The drug---alteration association was found in MM; (II) The association was found in other hematological malignancies; (III) The association was found in other cancers. The treating physicians then picked the drugs for repurposing keeping in mind the prior history of therapeutics administered, side effects and comorbidities in each individual patient. KRAS  15  G12D,  G12A,  G12C,  G12R,  G12V,  G13C,  G13D,  G60D,  Q22K,  Q61H,  Q61L,  Q61R,  Y64D   TP53  13  G187V,  E271*,  E349*,  E56K,  F113I,  H178P,  I232T,  L277Y,  L348F,  N239D,  P72A,  P72R,  V143M,  Splice  Site  17:7579591C>T  NRAS  9  G12S,  G13R,  Q61H,  Q61K,  Q61L,  Q61R  TTN  9  V10307A,  C7926Y,  G8488A,  H33348R,  I18825V,  I24457K,  P11785L, 
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